TY - JOUR
T1 - Gemcitabine-associated "Pseudocellulitis" and "Pseudosepsis"
T2 - A case report and review of the literature
AU - Obeid, Karam M.
AU - Venugopal, Anilrudh A.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Chemotherapeutic agents have been associated with sepsis and a variety of opportunistic and nonopportunistic infections. This was attributed to their immunosuppressive effects. Like all other chemotherapeutic agents, the use of gemcitabine has been associated with different infectious processes, yet many conditions that mimic infections have also been linked to its use. Pseudosepsis is a condition that should be added to these previously described conditions, such as gemcitabine-induced pseudocellulitis. We describe a patient who suffered from 2 different gemcitabine-induced adverse events including pseudocellulitis that was not related to prior lymphedema or radiation recall phenomenon and pseudosepsis wherein antibiotics have no role in the treatment, and the discontinuation of the offending agent resulted in the resolution of the patientÊ 1/4s symptoms.
AB - Chemotherapeutic agents have been associated with sepsis and a variety of opportunistic and nonopportunistic infections. This was attributed to their immunosuppressive effects. Like all other chemotherapeutic agents, the use of gemcitabine has been associated with different infectious processes, yet many conditions that mimic infections have also been linked to its use. Pseudosepsis is a condition that should be added to these previously described conditions, such as gemcitabine-induced pseudocellulitis. We describe a patient who suffered from 2 different gemcitabine-induced adverse events including pseudocellulitis that was not related to prior lymphedema or radiation recall phenomenon and pseudosepsis wherein antibiotics have no role in the treatment, and the discontinuation of the offending agent resulted in the resolution of the patientÊ 1/4s symptoms.
UR - http://www.scopus.com/inward/record.url?scp=84872955334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872955334&partnerID=8YFLogxK
U2 - 10.1097/MJT.0b013e3182204ffe
DO - 10.1097/MJT.0b013e3182204ffe
M3 - Article
C2 - 21768869
AN - SCOPUS:84872955334
SN - 1075-2765
VL - 20
SP - 118
EP - 120
JO - American journal of therapeutics
JF - American journal of therapeutics
IS - 1
ER -